Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
bioAffinity Technologies, Inc. logo

NASDAQ · BIAFW

bioAffinity Technologies, Inc.

Healthcare · Medical - Diagnostics & Research

$0.57

Down-$0.05 (-11.93%)

Updated Oct 11, 2026, 6:16 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.05M
P/E ratio
-0.12
Dividend yield
0.00%
52-week range
$0.05 – $0.98
Volume
270
Avg. volume
7.53K

Price performance · BIAFW

BIAFW price history

1M range · 16 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

BIAFW closed at $0.57 after 16 trading sessions, up 186.41% for the selected period.

Last close
$0.57
Period change
+186.41%
Period low
$0.13
Period high
$0.57
Daily close
View OHLC price history
BIAFW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.5671$0.5671$0.5671$0.5671270
Oct 8, 2026$0.60$0.6001$0.372$0.4093.86K
Oct 7, 2026$0.5399$0.5499$0.3551$0.521.92K
Oct 6, 2026$0.59$0.59$0.55$0.55219.6
Oct 5, 2026$0.733$0.733$0.3401$0.34011.88K
Oct 2, 2026$0.535$0.535$0.3796$0.52711.05K
Sep 30, 2026$0.32$0.32$0.32$0.32493.79
Sep 29, 2026$0.38$0.38$0.2801$0.28022.85K
Sep 28, 2026$0.30$0.38$0.26$0.262.26K
Sep 22, 2026$0.32$0.32$0.2615$0.321.29K
Sep 21, 2026$0.31$0.31$0.29$0.292.62K
Sep 18, 2026$0.26$0.3298$0.20$0.30023.2K
Sep 17, 2026$0.2479$0.4093$0.1764$0.230713.26K
Sep 16, 2026$0.22$0.22$0.1615$0.1615675
Sep 15, 2026$0.198$0.198$0.13$0.1323.14K
Sep 14, 2026$0.15$0.22$0.15$0.1983.18K

Latest BIAFW news

The latest Smart Investors Daily articles mentioning BIAFW.

Stock researchCompany · Overview

BIAFW research

Overview

Company profile and research snapshot.

Company profile

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per p

Yahoo · Oct 8, 2026

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant)

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By